Deep-pocketed investors have adopted a bullish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 22 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 36% bearish. Among these notable options, 7 are puts, totaling $484,655, and 15 are calls, amounting to $643,358.
Predicted Price Range
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $730.0 to $1100.0 for Eli Lilly during the past quarter.
Volume & Open Interest Development
In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 524.48 with a total volume of 1,224.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $730.0 to $1100.0 over the last 30 days.
Eli Lilly Option Volume And Open Interest Over Last 30 Days
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | PUT | SWEEP | BEARISH | 09/19/25 | $28.8 | $28.8 | $28.8 | $760.00 | $158.4K | 552 | 59 |
| LLY | CALL | TRADE | BULLISH | 09/19/25 | $62.7 | $62.25 | $62.7 | $790.00 | $125.4K | 384 | 5 |
| LLY | PUT | SWEEP | NEUTRAL | 06/18/26 | $94.95 | $87.25 | $90.33 | $800.00 | $90.4K | 139 | 10 |
| LLY | PUT | TRADE | NEUTRAL | 06/18/26 | $88.65 | $81.75 | $84.8 | $790.00 | $84.8K | 176 | 10 |
| LLY | CALL | TRADE | BULLISH | 01/16/26 | $107.7 | $105.15 | $106.71 | $780.00 | $53.3K | 158 | 8 |
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Eli Lilly's Current Market Status
- Currently trading with a volume of 717,763, the LLY's price is up by 0.2%, now at $807.05.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 13 days.
Professional Analyst Ratings for Eli Lilly
2 market experts have recently issued ratings for this stock, with a consensus target price of $1038.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * Consistent in their evaluation, an analyst from Guggenheim keeps a Buy rating on Eli Lilly with a target price of $942. * An analyst from Morgan Stanley has decided to maintain their Overweight rating on Eli Lilly, which currently sits at a price target of $1135.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from Benzinga Pro.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
